ATE530640T1 - Integrin-bindungsdomäne der map-kinase - Google Patents

Integrin-bindungsdomäne der map-kinase

Info

Publication number
ATE530640T1
ATE530640T1 AT01271913T AT01271913T ATE530640T1 AT E530640 T1 ATE530640 T1 AT E530640T1 AT 01271913 T AT01271913 T AT 01271913T AT 01271913 T AT01271913 T AT 01271913T AT E530640 T1 ATE530640 T1 AT E530640T1
Authority
AT
Austria
Prior art keywords
map kinase
binding domain
integrin
integrin binding
methods
Prior art date
Application number
AT01271913T
Other languages
English (en)
Inventor
Michael Agrez
Nuzhat Ahmed
Original Assignee
Inter K Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inter K Pty Ltd filed Critical Inter K Pty Ltd
Application granted granted Critical
Publication of ATE530640T1 publication Critical patent/ATE530640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
AT01271913T 2000-12-22 2001-12-21 Integrin-bindungsdomäne der map-kinase ATE530640T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR2305A AUPR230500A0 (en) 2000-12-22 2000-12-22 A method of modulating map kinase mediated cellular activity and agents useful in same
PCT/AU2001/001672 WO2002051993A1 (en) 2000-12-22 2001-12-21 MAP kinase integrin-binding domain

Publications (1)

Publication Number Publication Date
ATE530640T1 true ATE530640T1 (de) 2011-11-15

Family

ID=3826339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271913T ATE530640T1 (de) 2000-12-22 2001-12-21 Integrin-bindungsdomäne der map-kinase

Country Status (5)

Country Link
US (1) US7422883B2 (de)
EP (1) EP1352055B1 (de)
AT (1) ATE530640T1 (de)
AU (1) AUPR230500A0 (de)
WO (1) WO2002051993A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2418219B1 (de) 2003-10-17 2018-06-27 InterK Peptide Therapeutics Limited Verfahren und wirkstoffe zur behandlung von krebs
CA2579547A1 (en) * 2004-09-09 2006-03-16 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disease
US8080252B2 (en) * 2006-07-19 2011-12-20 The Cleveland Clinic Foundation Compounds and methods of modulating angiogenesis
WO2008104979A2 (en) 2007-02-28 2008-09-04 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
EP2537924B1 (de) 2007-03-27 2015-03-18 Intrexon Corporation MEK-Liganden und Polynukleotide zur Kodierung von MEK-Liganden
US20110105408A1 (en) * 2008-02-22 2011-05-05 Inter-K Pty Limited Therapeutic peptides
JP2012518602A (ja) * 2009-02-23 2012-08-16 インター−ケイ ピーティーワイ リミテッド 複数の細胞活性化経路の阻害
WO2013110120A1 (en) * 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
JP7644000B2 (ja) * 2018-05-15 2025-03-11 インテルク ペプチド セラピューティクス リミテッド 活性化剤
CN113166205A (zh) * 2018-11-30 2021-07-23 英特肽治疗有限公司 用于改善皮肤病状的多肽和方法
US20200319174A1 (en) * 2019-04-17 2020-10-08 Jiangnan University Method for Detecting Human Soluble Asialoglycoprotein Receptor
KR20240044517A (ko) * 2021-08-20 2024-04-04 인터크 펩타이드 테라퓨틱스 리미티드 암 및 암 요법과 연관된 자가면역을 포함한 자가면역을 치료하기 위한 조성물 및 방법
CN117269120B (zh) * 2022-06-20 2026-04-21 湘潭大学 一种基于磷光共振能量转移用于特异性检测信使rna的磷光生物传感器的制备及应用
CN116041482B (zh) * 2022-09-29 2024-05-03 江汉大学 一种结构肽段的cDNA、结构肽段和制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
CA2100352A1 (en) 1991-01-11 1992-07-12 Dean Sheppard Integrin .beta. subunit and uses thereof
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US6514745B1 (en) * 1993-07-19 2003-02-04 The Regents Of The University Of California Oncoprotein protein kinase
US5807746A (en) * 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US6495518B1 (en) * 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
WO1998016241A1 (en) 1996-10-15 1998-04-23 Vanderbilt University Method of disrupting cellular adhesion
US6007991A (en) * 1997-03-28 1999-12-28 The Research Foundation Of Suny Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer
ATE511850T1 (de) * 1997-08-08 2011-06-15 Univ California Behandlung von blasenfibrose mit antikörpern gegen alpha-v-beta-6-integrin
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6133246A (en) 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
ATE385503T1 (de) 1999-06-28 2008-02-15 Inter K Pty Ltd Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien
US6312956B1 (en) * 1999-10-01 2001-11-06 Vanderbilt University Nuclear targeted peptide nucleic acid oligomer
EP1303287A4 (de) 2000-06-16 2006-02-08 Argonex Pharmaceuticals In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung

Also Published As

Publication number Publication date
US7422883B2 (en) 2008-09-09
EP1352055A1 (de) 2003-10-15
EP1352055A4 (de) 2004-07-07
AUPR230500A0 (en) 2001-01-25
EP1352055B1 (de) 2011-10-26
US20050214755A1 (en) 2005-09-29
WO2002051993A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ATE530640T1 (de) Integrin-bindungsdomäne der map-kinase
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
MXPA00004256A (es) Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
BR9912327A (pt) Inibidores da uroquinase
CU23127A3 (es) Inhibicion de kinasa raf usando aril y heteroaril sustituidos en ureas heterociclicas
MXPA03003151A (es) Metodos de diagnostico de cancer de prostata, composiciones y metodos para seleccionar moduladores de cancer de prostata.
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
PL338339A1 (en) Novel derivatives of tetrazole
ATE257152T1 (de) N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia
DE59909760D1 (de) Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
BRPI0509177A (pt) uso de anticorpos anti-alfa5beta1 para inibir a proliferação de células cancerìgenas
ATE264328T1 (de) Substituierte 3-cyano-(1.7), (1.5) und (1.8)naphthyridininhibitoren von tyrosin kinasen
BR0108391A (pt) Citocinas modificadas para o uso em terapia de câncer
DE60029318D1 (de) Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen
DE60030164D1 (de) 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie
ATE356810T1 (de) Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
MXPA01010403A (es) Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
ATE233483T1 (de) Wässrige lösung zum konservieren von gewebe und organen
DE60019894D1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
TR200200169T2 (tr) IL-18 inhibitörlerinin kullanımı.
ATE315029T1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
DE60229414D1 (de) Verwendung von aplidine in der behandlung von pankreaskrebs
DK1064018T3 (da) Anvendelsen af isolerede domæner af Type IV kollagen til at modificere celle- og vævsinteraktioner
CY1105048T1 (el) Αγγελιαφορο pca3 ειδος rna σε καλοηθεις και κακοηθεις ιστους προστατη

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties